Editorial: Advances of endocrine and metabolic cardiovascular outcomes: From basic to clinical science, volume II

endocrine and metabolic diseases, this research topic (Volume II) aims to gather current developments emphasizing in this field, both in terms of basic and clinical aspects. We have collected 9 high-quality studies covering recent, novel, clinical significance in endocrine and metabolic cardiovascular diseases in our current research topics.Diabetic cardiomyopathy (DCM) is a serious complication of diabetes mellitus and is the leading cause of cardiac death in diabetic patients. Therefore, it is crucial to explore the pathogenesis of DCM and find new effective therapeutic targets. Ferroptosis, a novel mode of cell death, is not fully understood in the pathogenesis of DCM. Shi et al. obtained DCM model by intraperitoneal injection of streptozotocin in C57BL6 mice.Subsequently, the DCM mice were divided into two groups by the canagliflozin intervention and key aspects relevant to ferroptosis, such as total iron, Fe 2+ , transferrin receptor 1 (TfR1), ferritin heavy-chain (FTN-H), were investigated in vivo and in vitro.They found that canagliflozin attenuates the development of DCM by inhibiting ferroptosis. Through their research, we learned that ferroptosis may be involved in the process of DCM and prevention of ferroptosis may be effective in delaying the process of DCM. Moreover, Peng et al. focused on whether endothelial cell dysfunction is associated with DCM. The previous research discovered that an endogenous Snitrosothiol produced by eNOS called S-nitroso-L-cysteine (CSNO), may be connected to the insulin signaling pathway. In the current study, they demonstrate that CSNO treatment promotes glucose uptake by activating the insulin signaling pathway, glucose transporter 4 (GLUT4) membrane translocation. CSNO mitigates cardiomyocyte injury by reducing oxidative stress, autophagy hyperactivation and mitochondrial damage.The data from these studies will improve our understanding of how DCM occurs and offer novel therapy alternatives.With the in-depth study of the pathogenesis of diabetes, more and more glucoselowering drugs are used in the clinic. However, it has been a great challenge to explore therapies with good efficacy and few side effects for the overall benefit of patients.to assess short-term and long-term glycemic and cardiovascular benefits after washed microbiota transplantation (WMT) treatment and they identify that WMT not only improves short-and long-term blood glucose levels, but also has a more significant cardiovascular benefit. Effective glucose lowering by WMT may provide a new means for the treatment of diabetes, which requires more and more in-depth mechanistic studies to provide a theoretical basis.It is well known that nitric oxide (NO) is strongly associated with the development of vascular disease [3]. However, in addition to NO, there are many other gas molecules in the blood that contribute to vascular disease, and research in this area is relatively The current research subject covers the recent advancements in the study of endocrine and metabolic cardiovascular disease, including the new clinical trial index and the unique molecular regulation of basic research. Based on these findings, a more comprehensive understanding of endocrine and metabolic cardiovascular diseases can be achieved to provide mechanical insights in the pathogenesis and pathophysiology of ASCVD formation and more potential therapeutic targets may be identified. Regarding the close relationship between endocrine or metabolic disorders and downstream cardiovascular outcomes, a call for a new subspeciality in internal medicine, cardiometabolic or metabolic cardiovascular medicine, is indeed crucial in the future.